Cartilage-homing peptides

Patent metadata

Field	Value
Publication number	US-11090358-B2
Application number	US-201615758320-A
Country	US
Kind code	B2
Filing date	Sep 9, 2016
Priority date	Sep 9, 2015
Publication date	Aug 17, 2021
Grant date	Aug 17, 2021

Abstract

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

First claim

What is claimed:

1. A composition comprising a knotted peptide, the knotted peptide comprising a sequence having at least 90% sequence identity to SEQ ID NO: 327.

2. The composition of claim 1 , wherein the knotted peptide comprises:
(a) 4 or more cysteine residues; or
(b) a plurality of disulfide bridges formed between cysteine residues.

3. The composition of claim 1 , wherein the knotted peptide homes, targets, migrates to, accumulates in, binds to, is retained by, or is directed to a cartilage.

4. The composition of claim 1 , wherein the knotted peptide has a positive charge at physiological pH.

5. The composition of claim 1 , wherein the knotted peptide has a charge of at least 2 at physiological pH.

6. The composition of claim 1 , wherein the knotted peptide has an isoelectric point (pI) of greater than 7.4.

7. The composition of claim 1 , wherein the knotted peptide is linked to an active agent.

8. The composition of claim 7 , wherein the active agent comprises a therapeutic small molecule.

9. The composition of claim 8 , wherein the therapeutic small molecule comprises a steroid.

10. The composition of claim 9 , wherein the steroid comprises a corticosteroid.

11. The composition of claim 10 , wherein the corticosteroid comprises a glucocorticoid.

12. The composition of claim 11 , wherein the glucocorticoid is dexamethasone or budesonide.

13. The composition of claim 10 , wherein the corticosteroid comprises triamcinolone.

14. The composition of claim 13 , wherein the triamcinolone comprises triamcinolone acetonide.

15. The composition of claim 8 , wherein the therapeutic small molecule comprises a protease inhibitor.

16. The composition of claim 15 , wherein the protease inhibitor comprises a matrix metalloprotease 13 (MMP13) inhibitor.

17. The composition of claim 8 , wherein the therapeutic small molecule comprises an antibiotic, an anti-viral agent, an anti-fungal agent, an anti-inflammatory agent, or any combination thereof.

18. The composition of claim 17 , wherein the anti-inflammatory agent comprises a nonsteroidal anti-inflammatory drug (NSAID).

19. The composition of claim 7 , wherein the active agent comprises a peptide.

20. The composition of claim 19 , wherein the peptide comprises a cytokine, an enzyme, a growth factor, a chemokine, a neurotransmitter, an Fc region, or any combination thereof.

21. The composition of claim 7 , wherein the active agent comprises an immune modulator.

22. The composition of claim 7 , wherein the active agent comprises an antibody or an antibody fragment.

23. The composition of claim 7 , wherein the active agent comprises an anti-cytokine agent.

24. The composition of claim 7 , wherein the active agent comprises a therapeutic agent, a detectable agent, or a combination thereof.

25. The composition of claim 24 , wherein the detectable agent comprises: a fluorophore, a metal, a metal chelate, an X-ray contrast agent, a PET agent, a radioisotope, a photosensitizer, a radiosensitizer, a radionuclide chelator, or any combination thereof.

26. A pharmaceutical composition comprising the composition of claim 1 , and a pharmaceutically acceptable carrier.

27. The pharmaceutical composition of claim 26 , wherein the pharmaceutical composition is formulated for inhalation, intranasal administration, oral administration, intravenous administration, subcutaneous administration, intra-articular administration, intramuscular administration, intraperitoneal administration, administration locally into an affected area, administration into a joint, or any combination thereof.

Assignees

• Hutchinson Fred Cancer Res
• Blaze Bioscience Inc

Inventors

• Olson James
• Strand Andrew David
• Girard Emily June
• Strong Roland
• Mehlin Christopher
• Correnti Colin
• Nairn Natalie

Classifications

• A61K51/08

  Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} · CPC title

• A61K47/65

  Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers · CPC title

• A61K49/0032

  Methine dyes, e.g. cyanine dyes · CPC title

• A61K49/0056 Primary

  Peptides, proteins, polyamino acids · CPC title

• A61P19/04

  for non-specific disorders of the connective tissue · CPC title